This formulation combines Sildenafil 110mg and Tadalafil 20mg in a single tablet; pairing two PDE5 inhibitors that act on the same enzyme target through the same fundamental mechanism. Both compounds work by inhibiting PDE5, the enzyme that breaks down cyclic GMP following nitric oxide release during sexual stimulation, meaning this combination layers two inhibitors of the identical pathway rather than combining complementary or independent mechanisms.
It’s important to understand what combining two PDE5 inhibitors actually means pharmacologically, because it differs meaningfully from the rationale behind genuinely complementary combinations like Tri Mix, where each component acts through a distinct mechanism. Sildenafil and Tadalafil compete for the same PDE5 enzyme binding site. Taking both together does not produce two independent effects stacked on top of each other, since they are not acting on separate pathways. Combining PDE5 inhibitors is not standard clinical practice and is not something prescribing guidelines recommend, precisely because there is no established evidence that combining two PDE5 inhibitors produces a meaningfully better outcome than an adequate dose of either compound alone, while the combined dose increases the cumulative side effect burden from both compounds simultaneously.
At 110mg, the Sildenafil component alone exceeds the standard maximum recommended Sildenafil dose of 100mg, and the Tadalafil component is at its standard maximum of 20mg; meaning this tablet delivers two compounds each already at or above typical maximum recommended levels, in combination. This significantly increases the risk of dose dependent side effects including headache, flushing, visual disturbances, hypotension, and the nitrate interaction risk that applies independently to both compounds.
Every batch of CSD’s Superman V2 is third party lab tested for concentration accuracy and purity before being made available, with COA documentation available on request. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
This product combines two PDE5 inhibitors, each near or above standard maximum individual doses. This combination carries a significantly elevated risk of side effects compared to either compound alone, and must not be combined with nitrate medications under any circumstances, as the combined hypotensive risk is compounded by both compounds simultaneously. Strongly consult a healthcare provider before considering this product, particularly if you have any cardiovascular conditions, take other medications, or have not previously used either compound individually.
Store in a cool, dry place away from direct light and heat.